Adma Biologics (ADMA) Capital Expenditures (2011 - 2025)

Adma Biologics has reported Capital Expenditures for 13 years, with the latest figure at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 60.68% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $22.6 million (up 174.43% YoY), and the FY2025 full-year result was $22.6 million, up 174.43% from the prior year.
• Capital Expenditures for Q4 2025 stood at $1.1 million, down from $14.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $14.4 million in Q3 2025, with the low at $757000.0 in Q3 2023.
• Historically, Capital Expenditures has averaged $3.1 million across 5 years, with a median of $2.7 million in 2021.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 77.87% — and 2025, when it surged 1260.61%.
• Adma Biologics' Capital Expenditures stood at $3.7 million in 2021, then gained by 1.98% to $3.7 million in 2022, then tumbled by 68.07% to $1.2 million in 2023, then soared by 130.33% to $2.8 million in 2024, then sank by 60.68% to $1.1 million in 2025.
• The last three Capital Expenditures figures came in at $1.1 million (Q4 2025), $14.4 million (Q3 2025), and $2.4 million (Q2 2025), per Business Quant data.